FUSED BICYCLIC PYRIMIDINES

摘要

Disclosed are fused pyrimidine compounds, salts, tautomers, and stereoisomers of formula (I), wherein the substituents are as described within the specification. Examples of compounds of formula (I) include: 6-phenyl-7-(4-{ [4-(3-pyridin-2-yl-1,2,4-triazol-5-yl)piperidin-1-yl]methyl} phenyl)imidazo[1,2a]-pyrimidine; and Ethyl-6-phenyl-7-(4-{ [4-(5-pyridin-2-yl-1,2,4-triazol-3-yl)piperidin-1- yl]methyl} phenyl)imidazo[1,2-a]pyrimidine-2-carboxylate. Further disclosed is a pharmaceutical composition comprising at least one compound of formula (I), and a combination comprising one or more compounds of formula (I) and one or more second active agents selected from chemotherapeutic anti-cancer agents and target anti-cancer agents. Also disclosed is the of a compound of formula (I) for the production of a pharmaceutical composition for the treatment, prevention or amelioration of a disease mediated by a dysregulated function of a single protein kinase or multiple protein kinases and/or disorders responsive to the induction of apoptosis, and the treatment of benign and/or malignant neoplasia and cancer.